Artelo Biosciences’ ART12.11

Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study

Artelo Biosciences Inc. is one of the best-performing NASDAQ stocks according to analysts. On July 7, Artelo Biosciences announced positive preclinical efficacy data for its drug candidate, ART12.11, in a stress-induced depression model.

These findings were presented at the 35th Annual International Cannabinoid Research Society/ICRS Symposium, which was held from July 6 to 10 this year, in Bloomington, Indiana.

The preclinical data was presented in a poster titled “ART12.11, A Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms,” and showcased ART12.11’s unique dual-action profile.

In male rats exposed to chronic stress, a 28-day treatment regimen with ART12.11 reversed behavioral impairments, showing antidepressant-like effects comparable to sertraline (Zoloft), which is a selective serotonin reuptake inhibitor/SSRI. ART12.11 also restored hedonic and social behaviors, such as sucrose preference and social motivation, to near-baseline levels, similar to sertraline.

ART12.11 has superior cognitive restoration. Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, making it a differentiated therapeutic profile. This positions it as a potential next-generation treatment for depression and anxiety.

Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutics that target lipid-signaling pathways in the US.